Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

A trial tested an enhanced recovery after surgery (ERAS) protocol in patients who underwent ambulatory transurethral resection (TURBT) of bladder cancer.

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Please provide your email address to receive an email when new articles are posted on . Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large ...

Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial ...

“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...

Investigators observe no significant difference between the surgical approaches in 1-year progression rates. En bloc resection has the potential to improve outcomes in patients with non-muscle ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay between first sign and diagnosis can mean the difference between a ...

Patients with nonmetastatic node-positive bladder cancer may have similar survival rates whether they underwent treatment with surgery or radical dose radiotherapy. Patients with nonmetastatic ...